SLNSilence Therapeutics plc

Nasdaq silence-therapeutics.com


$ 21.68 $ -0.65 (-2.92 %)    

Thursday, 25-Apr-2024 15:59:33 EDT
QQQ $ 430.17 $ -2.06 (-0.48 %)
DIA $ 380.88 $ -3.52 (-0.92 %)
SPY $ 507.81 $ -1.92 (-0.38 %)
TLT $ 87.78 $ -0.62 (-0.7 %)
GLD $ 215.92 $ 1.28 (0.6 %)
$ 21.62
$ 22.27
$ 21.67 x 100
$ 0.00 x 0
$ 21.54 - $ 22.67
$ 4.60 - $ 27.72
324,153
na
2.57B
$ 1.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 morgan-stanley-maintains-overweight-on-silence-therapeutics-maintains-45-price-target

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and maintains $45 price tar...

 silence-therapeutics-announces-jama-publication-of-additional-apollo-phase-1-data-for-zerlasiran-in-subjects-with-elevated-lipoproteina

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

 these-analysts-boost-their-forecasts-on-silence-therapeutics-after-full-year-2023-results

Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.

 morgan-stanley-maintains-overweight-on-silence-therapeutics-raises-price-target-to-45

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target...

 chardan-capital-maintains-buy-on-silence-therapeutics-raises-price-target-to-42

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and raises the price target from $...

 hc-wainwright--co-maintains-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 pr...

 whats-going-on-with-silence-therapeutics-stock-today

Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Malli...

 silence-therapeutics-reported-2023-revenue-of-254m-eps-loss-of-389-cash-balance-of-540m

Financial Highlights for Year End 2023 Cash Position: Cash and cash equivalents of £54.0 million ($68.8 million) as of Decem...

 silence-therapeutics-announces-topline-36-week-data-from-ongoing-phase-2-study-of-zerlasiran-in-patients-with-high-lipoproteina

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology...

 earnings-scheduled-for-march-13-2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

 earnings-scheduled-for-march-12-2024

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.

Core News & Articles

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

 boeing-posts-upbeat-results-joins-stryker-automatic-data-processing-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday.

 bmo-capital-initiates-coverage-on-silence-therapeutics-with-outperform-rating-announces-price-target-of-67

BMO Capital analyst Kostas Biliouris initiates coverage on Silence Therapeutics (NASDAQ:SLN) with a Outperform rating and an...

 hc-wainwright--co-reiterates-buy-on-silence-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 p...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION